Related Experiment Video
Updated: Dec 22, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
[Treatment and secondary prevention of venous thromboembolism in cancer patients]
G A Shakaryants1, D A Budanova1, K V Lobastov2
1Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). Russian Federation, Moscow.
Abstract:
Oncological patients are a high-risk group for venous thromboembolic complications. These complications significantly impair the outcome of antitumor treatment and take a leading place in the structure of mortality. Treatment of venous thromboembolic complications in oncological patients is a serious challenge. When selecting an anticoagulant, the physician should consider its efficacy and safety and possible drug interactions. Based on results of multiple studies presented in this article, physicians will be able to choose an optimum therapeutic tactics and secondary prevention of thromboembolic complications for this group of patients.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism III: Nursing Management
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

